openPR Logo
Press release

Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Conference

11-02-2018 01:14 PM CET | Health & Medicine

Press release from: SMi Group

Superbugs & Superdrugs 2019

Superbugs & Superdrugs 2019

As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.

SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This year’s event aims to provide valuable insights and key updates on the latest developments within the scientific communities, as well as the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections.

The two-day conference will also host a diverse gathering of policy makers and economists, in addition to big pharmas and biotechs, who will discuss incentives, partnerships, regulations and new policies. Industry experts and scientific pioneers are set to present on their research advances and clinical data, as well as alternatives to antibiotics, such as monoclonal antibodies and antimicrobial peptides.

2019 Agenda Highlights:

• Analyse the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR
• Hear about novel immune-therapeutics to target Gram-negative bacterial infections
• Learn about strategies to combat β-lactamases
• Evaluate the development of precision antibiotics: Agents designed to meet the demands of stewardship
• Explore the role of plasmids in the evolution of antimicrobial resistance

Featured Expert Speakers:

• Mair Powell, Senior Medical Officer, HPRA
• John Rex, Chief Medical Officer & Director, F2G
• David Cook, Chief Scientific Officer, Blueberry Therapeutics
• David Roblin, President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Therapeutics
• Stephen A. Barat, Head of Pre-Clinical Research and Early Clinical Development, Scynexis
• Kazunori Maebashi, Senior Project Manager, Meiji Seika Pharma
• Chandrabali Ghose, CEO, Bioharmony Therapeutics
• Professor Eiríkur Steingrimsson, Co-founder, Akthelia Pharmaceuticals
• Chris Pickford, Head of Drug Discovery, Centauri Therapeutics
• Professor Christopher Schofield, Head of Organic Chemistry, Oxford University

Join us in London next year to explore the challenges and solutions to the growing threat of antibiotic resistance, as well as take part in interactive roundtable discussions with leading organisations. Attendees will also have the exclusive opportunity to network with an unrivalled gathering of internationally renowned senior experts at this year’s industry-leading event.

The brochure is now available to download on the website, with the full program of presentations and the official speaker line-up. Keep up to date with the latest conference news and learn more about the event at http://www.superbugssuperdrugs.com/openpr. Book your place before 30th November to save £400.

Superbugs & Superdrugs
18th & 19th March 2019
Holiday Inn Kensington Forum, London, UK

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Reports: Registration is now officially open for SMi’s Superbugs & Superdrugs Conference, returning for its 21st year to London, UK on the 18th and 19th March 2019.

SMi Group Ltd
1 Westminster Bridge Rd, South Bank, London SE1 7XW
Maria Mandic
mmandic@smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Conference here

News-ID: 1345981 • Views: 379

More Releases from SMi Group

Only 6 weeks to go until The Transdermal and Microneedle Delivery Conference
SMi Reports: Time is running out to Register for SM’s inaugural conference: Transdermal and Microneedle Delivery will take place on 24th - 25th January 2022 SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in
Only 6 weeks to go until the Pre-filled Syringes and Injectable Devices Conferen …
SMi Reports: Registration is open for SMi’s 14th Annual Conference and Exhibition taking place between 12th-13th January 2022 in London, UK. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is
SMi Presents the 16th Annual Conference: Parallel Trade 2022
SMi Presents the 16th Annual Conference: Parallel Trade 2022 Conference Date: 21st – 22nd March 2022 Workshop date: 23rd March 2022 Website: www.parallel-trade.com/ Navigating the challenges and legal landscapes of parallel trade SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together
The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffa …
SMi Reports: In preparation for the Inaugural Transdermal and Microneedle Drug Delivery Conference we hear from LEO Pharma Dr. Ester Caffarel-Salvador is a multidisciplinary scientist with a background in biotechnology and biochemistry. She was recognized by the MIT technology review with the Innovators under 35 award in 2019 and the Nova Talent award in 2021. As a postdoc in Professor Robert Langer's laboratory at MIT, she developed a novel pill design

All 5 Releases


More Releases for Superbugs

Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance. For interested individuals to attend
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. For this reason, the Superbugs & Superdrugs conference, taking
W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conf …
SMi Group reports: William J. Weiss - University of North Texas Health Science Center and Anthony Simon Lynch - Janssen supporting SMi's Superbugs & Superdrugs USA Conference, which is due to take place this November in New Jersey William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding,
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the
Antibiotic Drug Experts + Senior Industry Leaders set to Gather at Superbugs USA
SMi Group will open doors in 3 weeks to host the next annual USA Superbugs summit when it returns to Iselin, New Jersey on Nov 13th – 14th. http://www.superbugs-usa.com/opr Following over two decades of expertise in Europe, the USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline and resistance prevention. Highlights will include
Motif Biosciences Unveil Novel Solutions for the Treatment Deadly Superbugs
SMi Group will welcome the expertise of David Huang when he presents exclusive updates on Iclaprim, a novel diaminopyrimidine, for the treatment of serious gram- positive infections, at Superbugs & Superdrugs USA this fall. The talk will explore how Iclaprim addresses an unmet medical need in hospitalized patients with serious and life-threatening infections including MRSA. With over 15 years of clinical, academic, industry, and research experience in medicine and in the